Infosys Share Price

Nifty Share Price News Desk, 07 March 2026 Mumbai: Infosys Limited (NSE: INFY), a leading IT services company in India, has remained stable in the stock market. Since it’s Saturday and the market is closed, the latest price is up to 6 March 2026 (Friday). On the NSE, the share price was 1,308.40 rupees, while on the BSE it was 1,308.25 rupees. This article provides detailed information about Infosys’s share price, target and rating, financial position, order book and the latest news.

Share price update (NSE and BSE)

By 6 March 2026, Infosys shares remained stable. On NSE, the day’s open was ₹1,303, high ₹1,327.20, low ₹1,303 and close ₹1,308.40. The volume was 8.724 million shares, showing a 0.20% rise. On BSE, open was ₹1,304.85, high ₹1,327.15, low ₹1,304 and close ₹1,308.25. The volume was 222,654 shares, marking a 0.26% increase.

The stock’s 52-week high is 1,728 rupees and low is 1,264.10 rupees. The market cap is approximately 5,30,607 crore rupees. The stock has dropped -17.43% in three months, but the long-term outlook is positive.

Share price target and brokerage rating

Top brokerage firms have given positive targets and ratings for Infosys. The average target is ₹1,769.33, which shows a 35% upside from the current price.

  1. Morgan Stanley: Equal weight rating, target 1,760 rupees.
  2. BMO Capital: $20 target for NYSE ADR (currently $14.40), market perform rating.
  3. Nomura: Buy rating, target 1,810 rupees.
  4. PL Capital: Target 1,900 rupees.
  5. Choice Broking: Buy Rating, Target Rs 1,865.
  6. MK Global: Buy rating, target 1,750 rupees.

Out of a total of 44 analysts, 15 have given a strong buy, 12 have given a buy and 2 have given a sell rating. The average rating is ‘buy’, which is based on AI-driven growth and deal wins.

Financial situation (up to 7 March 2026)

Infosys’ FY26 Q3 (up to December 2025) results were positive, showing the company’s strong position. Q4 results haven’t been announced yet, but the FY26 guidance is 3-3.5% revenue growth (constant currency) and 20-22% operating margin.

Revenue: 45,479 crore rupees, YoY growth of 8.9%.
Net profit: 6,654 crore rupees, YoY down 2.2% (one-time provision of 1,289 crore due to new labour codes).
Operating margin: 18.4% (adjusted 21.2%).
Free cash flow: $915 million (adjusted $965 million).
EPS: Adjusted $0.21
Number of employees: +5,043, total 3,37,000.
ROE: 32.8%.

Although the company faced challenges due to US visa costs and Trump administration tariffs, it has stayed strong by focusing on AI and cloud.

Order book (until 7 March 2026)

Infosys’s order book is strong, showing future growth. In Q3, $4.8 billion TCV deals were won, 57% of which are new. This includes a $1.6 billion NHS (UK) deal. The order book for deals over $50 million is at a two-year high of $4.8 billion. This is because of AI-based partnerships, with AI projects with 90% of the top 200 clients.

Latest news update (up to 7 March 2026)

4 March 2026: High-value trading in Infosys shares, 3.1 million shares and a turnover of 406 crore. Outperformed in the sector, but down 17.43% over three months.

4 March 2026: Call option activity increased for March expiry, focus on strike prices 1,300, 1,320 and 1,400. Shows a bullish sentiment.
January-February 2026: Infosys and Intel expanded their strategic partnership for enterprise AI. In Q3, they gave an 85% performance bonus, the best in 3.5 years.
January 2026: Brand Finance recognised Infosys as the fastest-growing brand in IT services, with a brand value of $16.4 billion and a 15% CAGR.
January 2026: Shares rose 5% after Q3 results, FY26 revenue guidance upgraded to 3-3.5%

Infosys has stayed strong by focusing on AI, digital transformation and big deals. Investors should consider brokerage ratings and market trends. (Source: NSE, BSE, company reports and news agencies).

Disclaimer:
NiftySharePrice.com stock market news is based solely on publicly available, authentic data sources like NSE – BSE and SEBI-and US Market authorized brokers & analysts. Investing in the stock market involves risk. So, do your own research and consult your authorized advisors before investing.